KMT2A and acute myeloid leukemia: In a separate set of experiments tamoxifen-inducible KO of both Zeb1 and Zeb2 (although significant) did not extend the survival of mice transplanted with secondary MLL-AF9 AML (Fig 9C;p = 0.0031) over Zeb2 inactivation alone and if anything, decreased the overall survival between the 2 groups (70 days for Zeb2 KO alone versus 58 days median survival for Zeb1/2 DKO; Fig 9B and 9C).